{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:00:06Z","timestamp":1793322006571,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"\u201cThe value and mechanism of human carnitine palmitoyl transferase in the evaluation of hepatitis B associated hepatocellular carcinoma\u201d. Health Commission of Chengdu","award":["Project approval number: 2022386"],"award-info":[{"award-number":["Project approval number: 2022386"]}]},{"name":"\u201cThe mechanism of NLRP3 inflammasome axis regulating pyrodeath in secondary Streptococcus pneumoniae pneumonia after influenza virus infection\u201d. Chengdu Science and technology Bureau","award":["Project approval number: 2021-YF05- 00521-SN"],"award-info":[{"award-number":["Project approval number: 2021-YF05- 00521-SN"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03767-z","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T13:32:08Z","timestamp":1732023128000},"page":"2597-2604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of therapeutic effects and influencing factors of ICIs in lung-cancer patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Jun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0993-8296","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongGui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FangTing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"3","key":"3767_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3767_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391. https:\/\/doi.org\/10.1097\/CM9.0000000000001474.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3767_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","volume":"14","author":"U Majeed","year":"2021","unstructured":"Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108. https:\/\/doi.org\/10.1186\/s13045-021-01121-2. (PMID: 34238332; PMCID: PMC8264982).","journal-title":"J Hematol Oncol"},{"key":"3767_CR4","doi-asserted-by":"publisher","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009.","DOI":"10.1016\/j.jtho.2015.09.009"},{"issue":"11","key":"3767_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00432-014-1709-0","volume":"140","author":"H Wang","year":"2014","unstructured":"Wang H, Huang J, Yu X, Han S, Yan X, Sun S, Zhu X. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. J Cancer Res Clin Oncol. 2014;140(11):1901\u20139. https:\/\/doi.org\/10.1007\/s00432-014-1709-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3767_CR6","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1245\/s10434-018-6658-4","volume":"25","author":"T Pham","year":"2018","unstructured":"Pham T, Roth S, Kong J, Guerra G, Narasimhan V, Pereira L, Desai J, Heriot A, Ramsay R. An update on immunotherapy for solid tumors: a review. Ann Surg Oncol. 2018;25(11):3404\u201312. https:\/\/doi.org\/10.1245\/s10434-018-6658-4.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3767_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.clinthera.2020.12.017","volume":"43","author":"J Wu","year":"2021","unstructured":"Wu J, Zhang A, Li L, Liu S, Yang F, Yang R. Meta-analysis of the efficacy and tolerability of immune checkpoint inhibitors combined with chemotherapy in first-line treatment of small cell lung cancer. Clin Ther. 2021;43(3):582-593.e2. https:\/\/doi.org\/10.1016\/j.clinthera.2020.12.017.","journal-title":"Clin Ther"},{"issue":"5","key":"3767_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2217\/imt-2018-0110","volume":"11","author":"N Zhang","year":"2019","unstructured":"Zhang N, Tu J, Wang X, Chu Q. Programmed cell death-1\/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy. 2019;11(5):429\u201341. https:\/\/doi.org\/10.2217\/imt-2018-0110.","journal-title":"Immunotherapy"},{"key":"3767_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107322","volume":"184","author":"X Yan","year":"2023","unstructured":"Yan X, Qu F, Zhou Y. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases. Lung Cancer. 2023;184: 107322. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107322.","journal-title":"Lung Cancer"},{"key":"3767_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.013.","journal-title":"Lung Cancer"},{"key":"3767_CR11","doi-asserted-by":"publisher","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A, POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0.","DOI":"10.1016\/S0140-6736(16)00587-0"},{"issue":"5","key":"3767_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","volume":"21","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634\u201342. https:\/\/doi.org\/10.1634\/theoncologist.2015-0507.","journal-title":"Oncologist"},{"issue":"3","key":"3767_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00432-019-03104-w","volume":"146","author":"R Kitadai","year":"2020","unstructured":"Kitadai R, Okuma Y, Hakozaki T, Hosomi Y. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. J Cancer Res Clin Oncol. 2020;146(3):777\u201385. https:\/\/doi.org\/10.1007\/s00432-019-03104-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"3767_CR14","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.21873\/anticanres.12779","volume":"38","author":"T Shiroyama","year":"2018","unstructured":"Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T. Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Res. 2018;38(8):4723\u20139. https:\/\/doi.org\/10.21873\/anticanres.12779.","journal-title":"Anticancer Res"},{"issue":"8","key":"3767_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-019-0143-z","volume":"22","author":"Z Qiu","year":"2019","unstructured":"Qiu Z, Chen Z, Zhang C, Zhong W. Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 2019;22(8):19. https:\/\/doi.org\/10.1186\/s40164-019-0143-z.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"3767_CR16","doi-asserted-by":"publisher","first-page":"2253644","DOI":"10.1080\/2162402X.2023.2253644","volume":"12","author":"A Adamo","year":"2023","unstructured":"Adamo A, Frusteri C, Pilotto S, Caligola S, Belluomini L, Poffe O, Giacobazzi L, Dusi S, Musiu C, Hu Y, Wang T, Rizzini D, Vella A, Can\u00e8 S, Sartori G, Insolda J, Sposito M, Incani UC, Carbone C, Piro G, Pettinella F, Qi F, Wang D, Sartoris S, De Sanctis F, Scapini P, Dusi S, Cassatella MA, Bria E, Milella M, Bronte V, Ugel S. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients. Oncoimmunology. 2023;12(1):2253644. https:\/\/doi.org\/10.1080\/2162402X.2023.2253644.","journal-title":"Oncoimmunology"},{"issue":"4","key":"3767_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"3767_CR18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora JE, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O\u2019Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"issue":"4","key":"3767_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3233\/CBM-160336","volume":"19","author":"J Ding","year":"2017","unstructured":"Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353\u201363. https:\/\/doi.org\/10.3233\/CBM-160336.","journal-title":"Cancer Biomark"},{"issue":"4","key":"3767_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/cam4.2024","volume":"8","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Li Y, Yan X, Song Q, Wang G, Hu Y, Jiao S, Wang J. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Cancer Med. 2019;8(4):1467\u201373. https:\/\/doi.org\/10.1002\/cam4.2024.","journal-title":"Cancer Med"},{"issue":"9","key":"3767_CR21","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001\u20135 (Japanese).","journal-title":"Nihon Geka Gakkai Zasshi."},{"issue":"3","key":"3767_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s42000-018-0046-0","volume":"17","author":"C Efthymiou","year":"2018","unstructured":"Efthymiou C, Spyratos D, Kontakiotis T. Endocrine paraneoplastic syndromes in lung cancer. Hormones (Athens). 2018;17(3):351\u20138. https:\/\/doi.org\/10.1007\/s42000-018-0046-0.","journal-title":"Hormones (Athens)"},{"issue":"8","key":"3767_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17400","volume":"9","author":"H Xia","year":"2023","unstructured":"Xia H, Zhang W, Zheng Q, Zhang Y, Mu X, Wei C, Wang X, Liu Y. Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Heliyon. 2023;9(8): e17400. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17400.","journal-title":"Heliyon"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03767-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:17:04Z","timestamp":1747405024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03767-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["3767"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03767-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study is approved by the Ethics Committee of Chengdu Second People\u2019s Hospital. Written informed consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}